Table 3.

Frequency of Selected Adverse Maternal and Infant Outcomes and Adjusted Relative Risks for Receipt of Quadrivalent Human Papillomavirus Vaccine During Pregnancy and the Comparison Period, Vaccine Safety Datalink, 2007–2013

	Quadrivalent HPV Vaccine
Outcome	During Pregnancy (n=638)	During Comparison Period (n=8,196)	Adjusted RR* (95% CI)	Adjusted Risk Difference/100 Live Births (95% CI)
Chorioamnionitis	46 (7.2)	595 (7.3)	0.95 (0.70–1.3)	−0.3 (−2.4 to 1.8)
Hypertensive disorders	55 (8.7)	671 (8.2)	1.04 (0.79–1.4)	0.4 (−1.9 to 2.7)
Gestational diabetes	30 (4.7)	396 (4.9)	0.98 (0.67–1.4)	0.2 (−1.7 to 2.1)
Preterm delivery (less than 37 wk of gestation)	50 (7.9)	616 (7.6)	0.97 (0.72–1.3)	−0.3 (−2.5 to 1.9)
SGA, less than the 10th percentile	74 (11.7)	902 (11.1)	1.04 (0.82–1.3)	0.4 (−2.3 to 3.0)

HPV, human papillomavirus; RR, relative risk; SGA, small for gestational age.

Data are n (%) unless otherwise specified.

^*Propensity-adjusted, quintiles of propensity score included in the model parameterized as a five-category variable. Variables included in the model were site, maternal age, year of delivery, prenatal care index, poverty, pre-existing maternal conditions.